Advertisement

Topics

Eribulin mesylate.

06:00 EST 2nd March 2011 | BioPortfolio

Summary of "Eribulin mesylate."

Eribulin mesylate (Halaven; Eisai) - a synthetic analogue of the marine natural product halichondrin B that interferes with microtubule dynamics - was approved in November 2010 by the US Food and Drug Administration for the treatment of metastatic breast cancer.

Affiliation

Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.

Journal Details

This article was published in the following journal.

Name: Nature reviews. Drug discovery
ISSN: 1474-1784
Pages: 173-4

Links

DeepDyve research library

PubMed Articles [27 Associated PubMed Articles listed on BioPortfolio]

Antitumor Effects of Eribulin Mesylate in Gemcitabine-resistant Pancreatic Cancer Cell Lines.

One reason of poor survival rate of patients with pancreatic cancer is the development of chemoresistance. The aim of the present study was to investigate the effects of eribulin mesylate in gemcitabi...

Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.

Eribulin mesylate (eribulin) is currently indicated for treatment of locally advanced or metastatic breast cancer (MBC). It is a cytotoxic agent with unique mechanisms that suppress epithelial-mesench...

Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma.

Eribulin mesylate is a novel, non-taxane, synthetic microtubule inhibitor showing antitumor activity in a wide range of tumors including soft tissue sarcomas (STS). Eribulin has been recently approved...

Treatment of Heavily Pre-treated Metastatic Breast Cancer with Eribulin: First local experience in Sabah.

There are many options in the treatment of heavily pretreated metastatic breast cancer however none of the therapeutic agents have shown promising improvement of survival with good toxicity profile. E...

Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.

Despite the survival benefit and acceptable tolerability of eribulin for advanced/metastatic breast cancer (MBC) patients pretreated with anthracyclines and taxanes, there is limited evidence of the c...

Clinical Trials [395 Associated Clinical Trials listed on BioPortfolio]

To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors

The primary objective of this study was to assess the effect of cytochrome P450 3A4 enzyme (CYP3A4) induction by rifampicin on the pharmacokinetics (PK) of eribulin mesylate following intr...

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

This phase II trial studies how well eribulin mesylate works in treating patients with osteosarcoma that has come back after treatment (recurrent) or has not responded to treatment (refrac...

Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer

This phase II trial studies how well eribulin mesylate works in treating patients with advanced or recurrent cervical cancer. Drugs used in chemotherapy, such as eribulin mesylate, work in...

QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors

The purpose of this study is to assess whether eribulin mesylate (E7389) has an impact on the electrocardiogram (ECG) with focus on cardiac repolarization, as measured by QT/QTc interval a...

Neuropharmacokinetics of Eribulin Mesylate in Patients With Brain Metastases From Breast, Bladder, or Non-small Cell Lung Cancer

This pilot trial studies the concentration of eribulin mesylate in the brain of patients with breast, bladder, or non-small cell lung cancer that has spread to the brain (metastases). Drug...

Medical and Biotech [MESH] Definitions

Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Quick Search
Advertisement
 


DeepDyve research library

Searches Linking to this Article